Tenapanor + Sevelamer Carbonate
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, End Stage Renal Disease
Trial Timeline
Jun 15, 2019 → Jul 31, 2021
NCT ID
NCT03988920About Tenapanor + Sevelamer Carbonate
Tenapanor + Sevelamer Carbonate is a approved stage product being developed by Ardelyx for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03988920. Target conditions include Hyperphosphatemia, End Stage Renal Disease.
What happened to similar drugs?
1 of 14 similar drugs in Hyperphosphatemia were approved
Approved (1) Terminated (0) Active (13)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03988920 | Approved | Completed |
Competing Products
20 competing products in Hyperphosphatemia